Banner News

Taiwan, January 10, 2022 –Credo Diagnostics Biomedical Pte. Ltd. is delighted to announce that both VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets have obtained the CE IVD mark. These control sets are intended to be used for quality control testing with a series of VitaPCR™ Assays (exclude VitaPCR™ SARS-CoV-2 Assay, Cat# PCRAE0114)


VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets consist of droppers and disposable positive controls. The positive control is noninfectious in-vitro transcribed RNA in a lyophilized state, which can be conveniently stored at room temperature. With the control sets, the user is able to conduct quality testing to affirm the assay performance anywhere and anytime without the risk of control degradation and contamination.


VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets are recommended to be used during each time a new shipment of kits is received or when training a new operator; or in accordance with local regulations, accrediting groups, or laboratory’s standard quality control procedures.


For more information, please contact:



About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.


We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.